SRPT logo

SRPT
Sarepta Therapeutics Inc

26,738
Mkt Cap
$1.79B
Volume
823,674.00
52W High
$43.92
52W Low
$10.42
PE Ratio
-17.59
SRPT Fundamentals
Price
$17.07
Prev Close
$16.96
Open
$16.82
50D MA
$20.06
Beta
1.25
Avg. Volume
2.45M
EPS (Annual)
-$7.13
P/B
1.19
Rev/Employee
$2.63M
$2,254.48
Loading...
Loading...
News
all
press releases
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.
News Placeholder
More News
News Placeholder
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.
News Placeholder
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.
News Placeholder
Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock
Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock...
News Placeholder
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital...
News Placeholder
REPL, QURE, MRNA Soar On Reports Trump Will Fire FDA’s Marty Makary
The Wall Street Journal reported on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency.
News Placeholder
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.
News Placeholder
Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
News Placeholder
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth
The stock was weighed down after hours by lower sales reported for Sarepta’s gene therapy Elevidys.
News Placeholder
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +253.07% and +56.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available